NASDAQ:AARD Aardvark Therapeutics (AARD) Stock Price, News & Analysis $4.31 -0.23 (-5.07%) As of 10:47 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aardvark Therapeutics Stock (NASDAQ:AARD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aardvark Therapeutics alerts:Sign Up Key Stats Today's Range$4.31▼$4.6750-Day Range$3.51▼$6.7352-Week Range$3.35▼$17.94Volume36,639 shsAverage Volume244,140 shsMarket Capitalization$94.04 millionP/E RatioN/ADividend YieldN/APrice Target$19.70Consensus RatingHold Company Overview Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases. The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders. Leveraging a proprietary screening platform, structural biology capabilities and medicinal chemistry expertise, Aardvark has advanced multiple preclinical candidates toward IND-enabling studies. These programs are supported by in vitro and in vivo pharmacology, biomarker development and toxicology assessments conducted at the company’s Cambridge research facilities. Founded by a team of immunology and drug-development veterans, Aardvark Therapeutics is led by President and CEO Marshall Bolog, Ph.D. The leadership team combines translational pharmacology, clinical development and regulatory affairs expertise to guide the company’s pipeline through preclinical and early clinical stages. Aardvark pursues strategic collaborations with academic institutions and industry partners to enhance its RORγ portfolio and is positioned to advance its therapeutic candidates into human trials while exploring global licensing and development opportunities.AI Generated. May Contain Errors. Read More Aardvark Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreAARD MarketRank™: Aardvark Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 346th out of 867 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingAardvark Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 1 strong buy rating, 6 buy ratings, 4 hold ratings, and 2 sell ratings.Upside PotentialAardvark Therapeutics has a consensus price target of $19.70, representing about 357.1% upside from its current price of $4.31.Amount of Analyst CoverageAardvark Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Aardvark Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Aardvark Therapeutics are expected to grow in the coming year, from ($3.46) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aardvark Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aardvark Therapeutics is -1.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAardvark Therapeutics has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.78% of the float of Aardvark Therapeutics has been sold short.Short Interest Ratio / Days to CoverAardvark Therapeutics has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Aardvark Therapeutics has recently increased by 9.43%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAardvark Therapeutics does not currently pay a dividend.Dividend GrowthAardvark Therapeutics does not have a long track record of dividend growth. News and Social Media2.4 / 5News Sentiment-0.14 News SentimentAardvark Therapeutics has a news sentiment score of -0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aardvark Therapeutics this week, compared to 4 articles on an average week.Search Interest5 people have searched for AARD on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows2 people have added Aardvark Therapeutics to their MarketBeat watchlist in the last 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aardvark Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsAardvark Therapeutics has minimal institutional ownership at this time.Read more about Aardvark Therapeutics' insider trading history. Receive AARD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aardvark Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AARD Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDMay 21, 2026 | prnewswire.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSMay 21, 2026 | prnewswire.comOne page of the SpaceX S-1 will move this stock overnightWhen SpaceX files its S-1 in June, the SEC will require full disclosure of operating expenses - including power consumption for 1 million GPUs, a cost that rivals entire cities. That disclosure will name the supplier. One small, publicly traded power infrastructure company sits at the center of this - carrying a $1.5 billion backlog and priced like a utility. Dylan Jovine has the full breakdown.May 26 at 1:00 AM | Behind the Markets (Ad)Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of "Hold" from BrokeragesMay 21, 2026 | americanbankingnews.comAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens BermanMay 19, 2026 | prnewswire.comAardvark Therapeutics: Regulatory Uncertainty Clouds ARD-101 Path ForwardMay 18, 2026 | seekingalpha.comFDA hold puts Aardvark Prader-Willi drug in limboMay 15, 2026 | finance.yahoo.comAARD stock crashes 34% – here’s why this analyst finds it ‘hard to lean into’ Aardvark at this stageMay 15, 2026 | msn.comSee More Headlines AARD Stock Analysis - Frequently Asked Questions How have AARD shares performed this year? Aardvark Therapeutics' stock was trading at $13.13 at the beginning of 2026. Since then, AARD stock has decreased by 67.2% and is now trading at $4.31. How were Aardvark Therapeutics' earnings last quarter? Aardvark Therapeutics, Inc. (NASDAQ:AARD) posted its quarterly earnings results on Thursday, May, 7th. The company reported ($0.99) EPS for the quarter. When did Aardvark Therapeutics IPO? Aardvark Therapeutics (AARD) raised $100 million in an initial public offering on Friday, February 14th 2025. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cantor and RBC Capital Markets acted as the underwriters for the IPO. Who are Aardvark Therapeutics' major shareholders? Top institutional shareholders of Aardvark Therapeutics include Renaissance Technologies LLC (0.32%), Bank of New York Mellon Corp (0.13%) and Bank of America Corp DE (0.05%). Insiders that own company stock include Tien-Li Lee and Nelson Sun. View institutional ownership trends. How do I buy shares of Aardvark Therapeutics? Shares of AARD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/07/2026Today5/26/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 13 days, AARD's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AARD Previous SymbolNASDAQ:AARD CIK1774857 WebN/A Phone(858) 225-7696FaxN/AEmployees18Year Founded2017Price Target and Rating Average Price Target for Aardvark Therapeutics$19.70 High Price Target$47.00 Low Price Target$3.00 Potential Upside/Downside+357.1%Consensus RatingHold Rating Score (0-4)2.46 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$57.59 million Net MarginsN/A Pretax MarginN/A Return on Equity-61.71% Return on Assets-56.29% Debt Debt-to-Equity RatioN/A Current Ratio8.06 Quick Ratio8.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.99 per share Price / Book1.08Miscellaneous Outstanding Shares21,820,000Free FloatN/AMarket Cap$94.04 million OptionableN/A Beta5.11 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:AARD) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredNo. You’re not imagining it…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aardvark Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aardvark Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
